fashion -WSS

fashion

author：comprehensive 2025-09-06 02:03:52 - browse：779

This image provided by Eisai in January 2023 shows vials and packaging for their medication, Leqembi. — Illustration: Alex Hogan/STAT; Photo: Eisai via AP

Seven months after US drug regulators fully approved Biogen’s treatment for Alzheimer’s disease, only about 2,000 patients are taking the medicine nationwide, the company said Tuesday.

Biogen’s chief executive, Christopher A. Viehbacher, said as the firm released fourth-quarter earnings that he had expected the slow uptake and sees considerable demand for the medication. He told reporters that 3,800 patients with early-stage Alzheimer’s have signed up on multiple registries to receive the drug, called Leqembi, as of last month.

Before patients can get the drug, which costs $26,500-a-year, they must undergo a brain scan or a spinal tap to confirm that they have build-up of deposits of a sticky toxic protein called beta-amyloid that is a hallmark of the disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Cancer cells are shown to suck energy source from immune cells

focus

WSS

Study says nonprofit hospitals fall short in charity care spending

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

There’s no way to know how good AI health technologies are

Supreme Court mifepristone arguments center on docs' right to sue

STAT Readout: Today's biotech news includes Sana and Amylyx

The Readout: Lenmeldy, GLP

Wikipedia

fashion

knowledge

Affirmative action in medical school literally saved lives

Why the world’s most expensive drug might be worth the price

Tori Bowie and the unacceptable rates of Black maternal death

Donor acceptance rates hint at racial, gender bias in heart transplants: study

At least 13 dead in Texas as scorching temps continue

There’s no way to know how good AI health technologies are

Trump demands the U.S. pay no more for drugs than other countries … again

How clinical AI models' predictive power can degrade over time

Jerome Adams on the need for new antivirals for Covid

Covid vaccine financial winners and losers, from Pfizer to Novavax

entertainment

FDA's naming rule on biosimilars has undermined competition

Covid vaccine financial winners and losers, from Pfizer to Novavax

Cancer cells are shown to suck energy source from immune cells

Will generative AI in health care meet the fate of IBM's Dr. Watson?

How clinical AI models' predictive power can degrade over time

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

entertainment

focus

focus

focus